Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.15 | — | — | 2.77 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.99 | 2.49 | 27.17 | 13.68 | 1.59 | 1.09 | 4.62 | 8.96 | 5.52 | 4.42 | — | — | — | — | — | — | — | — | — | — | — |
| — | +128.1% | +488.7% | +52.8% | -71.2% | -75.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 21.35 | 2.57 | 18.95 | 21.23 | — | 4.99 | 5.06 | 3.51 | 2.38 | 1.25 | 1.17 | 0.41 | 1.11 | 1.07 | 1.03 | 0.70 | 0.63 | 0.55 | 1.16 | 1.73 | — |
| — | -48.4% | +274.8% | +505.0% | — | +299.9% | +332.2% | +752.8% | +115.5% | +16.7% | +14.1% | -41.0% | +75.2% | +92.6% | -11.9% | -59.7% | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | 0.47 | — | — | 0.52 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 14.92 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.5% | 100.0% | 97.3% | 100.0% | 100.0% | -89.6% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — | — | — | — | — | — |
| — | +211.6% | -2.7% | 0.0% | 0.0% | -189.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -95.9% | -18.7% | -111.6% | -86.5% | -10.1% | -177.7% | -472.7% | -790.5% | -652.3% | -623.8% | — | — | — | — | — | — | — | — | — | — | — |
| — | +89.5% | +76.4% | +89.1% | +98.4% | +71.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -80.1% | -34.1% | -75.3% | 75.7% | -85.4% | -196.0% | -452.7% | -759.5% | -619.5% | -590.8% | — | — | — | — | — | — | — | — | — | — | — |
| — | +82.6% | +83.4% | +110.0% | +86.2% | +66.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -132.5% | -8.8% | -17.7% | 76.2% | — | -178.3% | -93.8% | -67.9% | -51.6% | -47.1% | -55.0% | -39.5% | -27.9% | -25.4% | -23.8% | -19.4% | -14.6% | -15.9% | -12.1% | -80.5% | — |
| — | +95.1% | +81.1% | +212.3% | — | -279.0% | -70.6% | -71.7% | -84.5% | -85.0% | -131.1% | -104.1% | -91.0% | -60.4% | -95.8% | +75.9% | — | +22.9% | +56.8% | — | — | |
| ROA | -31.0% | -4.0% | -6.0% | 7.2% | -12.2% | -13.3% | -15.2% | -18.0% | -17.0% | -16.1% | -24.0% | -25.4% | -19.7% | -19.0% | -18.1% | -15.2% | -11.8% | -13.1% | -10.2% | -11.5% | -12.5% |
| — | +69.9% | +60.5% | +140.0% | +28.5% | +17.4% | +36.7% | +29.4% | +13.4% | +15.0% | -32.7% | -68.0% | -66.8% | -44.4% | -76.8% | -31.6% | +5.4% | +15.4% | +40.3% | +79.9% | — | |
| ROIC | — | — | — | — | — | — | — | — | — | — | -608.7% | -252.7% | -162.9% | -163.7% | -237.9% | -260.5% | -229.7% | -238.4% | -172.0% | — | — |
| — | — | — | — | — | — | — | — | — | — | -155.8% | +3.0% | +29.1% | +31.3% | -38.3% | — | — | +60.1% | +92.2% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.09 | 0.09 | 0.20 | — | 1.07 | 0.73 | 0.46 | 0.40 | 0.26 | 0.35 | 0.31 | 0.28 | 0.25 | 0.21 | 0.19 | 0.17 | 0.14 | 0.13 | 0.11 | — |
| — | -91.9% | -87.5% | -57.4% | — | +311.9% | +111.7% | +48.7% | +45.7% | +4.2% | +62.5% | +64.8% | +65.7% | +77.7% | +67.1% | +68.8% | — | -31.3% | -25.5% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.58 | 4.25 | 3.59 | 2.58 | 2.20 | 2.32 | 1.96 | 2.21 | 1.67 | 2.02 | 2.19 | 3.02 | 3.81 | 4.81 | 5.99 | 5.89 | 8.45 | 9.17 | 14.81 | 15.85 | 8.20 |
| — | +83.1% | +83.5% | +16.6% | +32.1% | +15.1% | -10.7% | -26.7% | -56.3% | -58.1% | -63.4% | -48.8% | -54.9% | -47.5% | -59.6% | -62.8% | +3.0% | +56.9% | +69.2% | +1605.4% | — | |
| Quick Ratio | 2.58 | 4.25 | 3.59 | 2.58 | 2.20 | 2.32 | 1.96 | 2.21 | 1.67 | 2.02 | 2.19 | 3.02 | 3.81 | 4.81 | 5.99 | 5.89 | 8.45 | 9.17 | 14.81 | 15.85 | 8.20 |
| — | +83.1% | +83.5% | +16.6% | +32.1% | +15.1% | -10.7% | -26.7% | -56.3% | -58.1% | -63.4% | -48.8% | -54.9% | -47.5% | -59.6% | -62.8% | +3.0% | +56.9% | +69.2% | +1605.4% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | -175.55 | -86.81 | -95.78 | — | — | — | — | -164.53 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying XLO stock.
Xilio Therapeutics, Inc.'s current P/E is -2.2x. The average P/E over the last 1 quarters is 2.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Xilio Therapeutics, Inc.'s current operating margin is -95.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Xilio Therapeutics, Inc.'s business trajectory between earnings reports.